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ABSTRACT
Immediate and non-immediate hypersensitivity reactions to iodinated contrast media (ICM) have 
been reported to occur in a frequency of about 0.5-3% of patients receiving non-ionic ICM. The 
diagnosis and management of these patients varies  among guidelines published by various 
national and international scientific societies, with recommendations ranging from avoidance or 
premedication to drug provocation test. This position paper aims to give recommendations for the 
management of patients with ICM hypersensitivity reactions and analyze controversies in this 
area. 
Skin tests are recommended as the initial step for diagnosing patients with immediate and non-
immediate hypersensitivity reactions; besides, they may also help guide on tolerability of 
alternatives. Reexposition or drug provocation test should only be done with skin test-negative 
ICMs.The decision for performing either reexposition or drug provocation test needs to be taken 
based on a risk-benefit analysis. The role of in vitro tests for diagnosis and pretreatment for 
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INTRODUCTION
Adverse events after iodinated contrast media (ICM) administration may be either hypersensitivity 
reactions (type B reactions) or toxic reactions (type A reactions) (1, 2). According to the time 
interval between ICM administration and appearance of symptoms, hypersensitivity reactions are 
divided into immediate reactions (IHR), which occur within 1 to 6 h after ICM administration, or 
non-immediate reactions (NIHR), appearing more than 6 h after ICM exposure (2-5). Both IHR 
and NIHR have been reported to occur in a frequency of about 0.5-3% of patients receiving non-
ionic ICM (3). 
IHR induce anaphylaxis, urticaria, angioedema, sometimes together with vomiting, abdominal 
pain, diarrhea, or more severe reactions affecting the respiratory and cardiovascular systems 
presenting with dyspnoea, bronchospasm and/or a sudden drop in blood pressure (2-7). 
Hypotension may be associated with loss of consciousness (anaphylactic shock). In about 70% of 
these reactions, the onset is within 5 min after injections (8).
NIHR commonly manifest as maculopapular exanthema (MPE), and rarely as more severe 
reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), fixed drug 
eruption (FDE), drug reaction with eosinophilia and systemic symptoms (DRESS), symmetric 
drug-related intertriginous and flexural exanthema (SDRIFE), or acute generalized 
exanthematous pustulosis (AGEP) (2, 3, 5-7, 9). In addition, delayed appearing urticaria or 
angioedema may occur, especially within the first 6 hours after ICM administration. 
The management of patients with previous hypersensitivity reactions to ICM varies among 
guidelines published by various national and international scientific societies, with 
recommendations ranging from avoidance or premedication to drug provocation test (DPT) (3, 10, 
11) (Table 1). This position paper aims to give recommendations for the management of patients 
with ICM hypersensitivity reactions and analyze controversies in this area. It updates previous 
recommendations by the EAACI IG Drug Allergy/European Network on Drug Allergy 
(IGDA/ENDA) taking into account new data and developments (3). 
METHODS
This position paper was commissioned by the European Academy of Allergy and Clinical 
Immunology (EAACI). It is based on evidences as well as on expert opinion. The preparation 
included a literature search in MEDLINE by the members of the Task Force Group focusing on 
the search of the words (radio and iodinated) contrast hypersensitivity, adverse reactions, 
hypersensitivity, and allergy. We restricted the content of this paper to hypersensitivity reactions. 
During the development of these guidelines, the consultation process included meetings in 
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conference in November 2018, and in June 2019 in Lisbon. Comments, suggestions, and 
recommendations were carefully considered and consented by the whole group. For each 
statement, the quality of evidence and recommendation was graded and discussed, confirmed, or 
amended by consensus of the Task Force members. Grading for key statements was performed 
adopting the GRADE system (12). Evidence was graded as high, low, or very low based on 
expert opinion considering available evidence, because no systematic review was done. The 
strength of the recommendations was strong or weak, that is, the grading of low/strong in the text 
denotes a low quality of evidence or great strength of recommendation. 
IMMEDIATE HYPERSENSITIVITY REACTIONS 
The mechanism underlying IHRs to ICM is still a matter of controversy (6) and, although in the 
majority of patients the mechanism is non-allergic, in some cases IgE-mediated allergic reactions 
are reported (6, 13-16). The presence of positive skin tests (ST) and basophil activation tests 
(BAT), and older studies reporting detection of low levels of specific IgE to ionic ICM indicate an 
IgE-mediated mechanism (6, 13-21). Histamine and tryptase serum levels (15, 19, 20), as well as 
the frequency of positive allergy diagnostic tests, increase with the severity of the reaction (6, 10, 
13, 20, 21). A recent multicentre prospective study documented allergy in one in tenth, a quarter, 
half and all patients with cutaneous, moderate-systemic, life threatening anaphylaxis and cardiac 
arrest, respectively (20). The risk for IgE-mediated allergy increases when three or four different 
organs are affected simultaneously, especially when cardiovascular symptoms appear in 
combination with respiratory or cutaneous reactions (20). In contrast, non-allergic reactions are 
likely when only one organ is affected (20, 21).
IHRs in the context of a contrast-enhanced image-guided procedure are in most cases (74%) 
contrast media-induced reactions (22). In the remaining 26%, other culprit substances/cases such 
as latex, adenosine, or vasovagal reaction could be identified (22).  
1.- What are indications for testing?
a) Background: The most significant risk factor for an IHR to a ICM is a previous immediate 
reaction. Other presumed risk factors (gender, asthma, atopy, allergy to other drugs) (23) have 
shown inconsistent results and therefore cannot be used as pre-requisite for performing ICM 
allergy work-up. 
b) Practical statement: Allergy testing is indicated in patients with history of IHR. There are no 
indications for testing patients labelled as “iodine allergy” (povidone iodine, crustaceans, and 
mollusk) as well as patients with food, respiratory, cutaneous, drug allergies, but no previous 
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pruritus, heat sensation, transient erythema, flushing, dizziness, nausea, sneezing, rhinorrhea, 
chest tightness) or localized cutaneous reaction (isolated wheals, erythema) at the ICM injection 
site.
Recommendations 
- To perform allergic work-up in patients with a history of ICM-induced anaphylaxis 
(strong/moderate). 
- To perform it in patients with a history of ICM-induced isolated urticaria, angioedema, or 
bronchospasm (weak/low).  
2.- How to perform skin testing?
a) Background: IHRs to ICM have traditionally been perceived as non-allergic reactions (24), 
therefore ST has been considered as an inappropriate tool for the diagnosis of such reactions, 
although this view has changed by newer evidence (25). The sensitivity of STs in IHR varies from 
4.2% to 73% among different studies (6, 13, 26-30). A meta-analysis revealed positive rates of 
17% (95% CI, 10–26%), being up to 52% (95% CI, 31-72%) for severe reactions (29). In a large 
study, positive STs were observed in 26% of patients reporting IHR; 3% had positive skin prick 
test (SPT) and 25% positive intradermal test (IDT) (6). The specificity of SPT is estimated at 
94.6% and of IDT 91.4%-96.3% (6, 30). Negative predictive value (NPV) of ST with ICM has been 
reported to be 93% (95% confidence interval, 86-96%) in a meta-analysis (29). A French study 
reported high NPV of skin testing for ICM (94.2% (95% CI 89.6% to 97.2%) for IHR) (21). Only 
one Spanish study reported that only 62.5% of their patients were diagnosed by ST and 37.5% by 
drug provocation test (DPT) (26). In the same centre, NPV were 97.3% or 80% when DPT was 
done by injecting 10 mL or 50 mL, respectively (31).
Such variability may be due to patient selection, , the clinical symptoms of the patients, their 
severity, the ICM substance used, the time between the reaction and the study and that DPT 
cannot differentiate allergic from non-allergic IHR as it is the case with other drugs (32-34). If this 
time is within 2-6 months, 50% of patients tested show positive results, decreasing to up 18% for 
patients tested at other time points (earlier than 2 months or later than 6 months) (6). The reason 
for this fact may be the limited duration of skin reactivity due to IgE clearance (35).
b) Practical Statement: SPT and IDT should be performed according to EAACI Guidelines (36). 
ICM should be used undiluted at the iodine concentration of 300-320 mg/ml for SPT and diluted 
1:10 for IDT (5, 6). STs should be performed with the ICM involved in the reaction, if known (5, 
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results to the culprit (6). It has been reported that a total of 18.2% were positive to two ICM and 
27.3% to three or more (6). Therefore, STs should be performed with the broadest possible panel 
of ICM available in the department if the result is positive, or if the culprit is unknown (5, 10). 
Recommendations 
- When to test: STs are preferably performed within 2-6 months after the reaction (weak /low).
- What to test: STs should be performed with the ICM involved in the reaction if known (strong 
/high). If the result is positive, or if the culprit ICM is unknown, STs should be performed with the 
broadest possible panel of ICM (strong /moderate).
- How to test: ICM should be used undiluted at 300-320 mg/ml for SPT and diluted at 1:10 for IDT 
(strong /moderate). STs should start by performing SPT and, if negative, continue with IDT 
(strong/moderate). 
3.- What is the value of in vitro testing?
There are different in vitro methods used in IHR to ICM: histamine, tryptase, and cysteinyl 
leukotrienes (cysLT) determination at the acute phase of the reaction, and BAT for identifying the 
ICM involved in the reaction once the reaction has resolved.
3.1. Histamine, tryptase, and cysteinyl leukotrienes 
a) Background: Histamine is released from mast cells and basophils after IgE-mediated reactions 
and concentrations measured in plasma few minutes after reactions correlate with severity. 
Histamine can also be released from basophils in vivo through non-IgE-mediated pathways (14, 
15, 38) . Tryptase is continually secreted by mast cells in tissues, and then it diffuses into the 
circulation, where it can be measured as protryptase. This can undergo additional processing 
within the cell to become mature tryptase, which is secreted only during mast cell activation. De 
novo synthesized cysLT may also mediate ICM-induced IHR (39).
b) Practical Statement: Histamine and tryptase can be both measured to confirm IHR to ICM. 
However, histamine is degraded quickly, being less specific and more complicated to measure by 
commercially available assays. Thus, tryptase is regarded as the preferred mediator. The 
approach is to compare acute (within 4 h of the event) and baseline total tryptase levels (at least 
24 h after all signs and symptoms of the event have subsided) to distinguish between an 
increased mast cell burden (e.g., mastocytosis, in which baseline tryptase levels remain elevated) 
and mast cell degranulation (with only acute tryptase levels elevated). The minimal elevation of 
acute over baseline tryptase levels suggested to be clinically significant is calculated as at least 2 
ng/ml+ [1.2 × baseline tryptase level] (40) or at least 20% above baseline plus 2 ng/mL during or 
within 4 h after a symptomatic period (41). An increase from baseline level during allergic 
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indicative of IgE-mediated mast cell activation and correlate with the clinical severity of the 
reaction (15, 20, 42). 
Recommendation 
- Tryptase determination at the acute phase is useful for confirming IHR to ICM, if a transient 
increase is detectable (strong /moderate). 
3.2. Basophil activation tests
a) Background: BAT is a flow cytometry-based cellular assay that measures activation of 
basophils upon allergen stimulation. It has shown utility for diagnosing IHR to drugs (28, 43). 
Regarding ICM, three studies demonstrate a BAT sensitivity of 46-63% depending on the 
threshold chosen, and a specificity of 89-100% (13, 26, 44). The area under the ROC curve was 
0.79 (95% confidence interval 0.67– 0.91, p<0.0001) by using the stimulation index as the 
diagnostic criteria with 1:100 dilution of RCM (44). 
b) Practical Statement: BAT can be a complementary tool to diagnose IHR to ICM (5), showing 
good correlation with ST and DPT results (26). It may be especially useful in cases with severe 
reaction and contraindications for ST or DPT (5). It is important to take into account that certain 
factors may affect BAT result, such as the time between the reaction and the test or the severity 
and type of reaction (26). However, the NPV has not been clearly determined (45). In addition, it 
has to be considered that about 10% of patients have non-reacting basophils (positive-control 
negative), rendering this test unsuitable for these patients.  
Recommendation
- BAT can be an additional tool for diagnosing patients with IHR with severe reactions or those 
with high risk (weak /low). 
4.- Is there a role for Drug Provocation Test?
a) Background: DPT is the final step of the diagnostic algorithm because of potential risk to the 
patient and it is used when there is no other available diagnostic tool. Moreover, it can be used to 
find a safe alternative. However, controversy still exists about the need of DPT with ICM, with 
most studies coming from Europe (10, 21, 26, 31, 32, 37, 46, 47). In the American Guidelines 
there is no statement favouring DPT with ICM in IHRs (48). Studies from Japan indicated severe 
reactions to very small “pre-test doses” (49), which has hampered development of DPT for many 
years. Even in patients without reaction to “pretesting”, severe reactions have been reported 









This article is protected by copyright. All rights reserved
testing as a tool for risk stratification prior to re-exposure; therefore, potential IgE-mediated 
allergic patients were left unidentified. New studies seem to indicate that DPT could be a safe 
procedure, presenting the same risks as with other drugs when higher doses are used and it is 
performed in experienced centres (10, 13, 26, 32).  
Administration of ICM is potentially harmful. Besides hypersensitivity reactions, they can induce 
contrast-induced acute kidney injury, which may lead to end-stage renal disease and even death, 
thyrotoxic crisis, and lactic acidosis. Therefore, only trained allergists who adhere to necessary 
safety recommendations should perform DPTs with ICM.  
b) Practical Statement: Either reexposition in a needed  radiologic examination or DPT can be 
done either to confirm tolerance with the ST negative culprit ICM or with an ST-negative 
alternative ICM in patients with positive ST to the culprit ICM, or in patients with an anaphylactic 
reaction in which administering the culprit is contraindicated (5, 9). A DPT should be considered 
in very severe IHRs. 
A broad safety check is necessary in every patient who will undergo DPT with ICM, especially in 
patients with kidney risk factors. It is recommended to determine the serum creatinine, to 
calculate the estimated Glomerular Filtration Rate (eGFR) and to monitor these parameters after 
DPT. DPT is contraindicated in patients with risk factor for kidney injury and renal insufficiency, 
in patients who receive nephrotoxic medication, in patients with contrast-enhanced image guided 
examination less than one week ago, or in whom a diagnostic contrast administration is planned 
in the next 1-7 days. DPT is also contraindicated in patients who will undergo a radioiodine 
therapy as well as in patients with hyperthyroidism. Pregnant and breast-feeding women should 
be excluded from DPT. Metformin medication should be stopped 24h before the DPT, and can be 
reintroduced if the follow-up does not reveal a renal function alteration. As prophylaxis against 
renal damage it is recommended to give low-osmolality or isosmolar ICM and  check renal 
function before injection (27).
As with other drugs, there is no consensus regarding the dose of ICM during DPT, with doses 
ranging from 49 to 100 mL. The protocols are: (i) 5-15-30-50 mL (cumulative dose = 100 mL) at 
45-min intervals (26); (ii) 0.05-0.5-1-5-7.5-10-25 mL (cumulative dose = 49.05 mL) at 30-min 
intervals (51).
Recommendations 
- Either reexposition or DPT can be performed to confirm tolerance to a skin test-negative ICM; 
the decision is based on availability of DPT and risk-benefit analysis (strong/high). 
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- Available protocols should be standardized and validated (strong /high).
- Renal function needs to be carefully monitored (strong/high).
- As in any DPT, the decision need to be taken based on a risk-benefit analysis of each patient 
and should be done only in well-equipped centres and by trained personnel in immediate 
emergency treatment (strong /low). The possibility to perform the DPT together with the 
radiological examination should be considered  (strong /low). 
- DPT is not indicated in patients at risk (renal complaints, hyperthyroidism, radioactive iodine 
therapy, pregnant and breast-feeding women, nephrotoxic medication, etc.) (strong/high).  
5.- How should a patient be evaluated? 
a) Background: Patients with a history of an IHR to ICM may react again upon renewed 
administration of ICM (52). But in cases reporting a mild ICM-induced IHR limited to the skin, the 
risk of developing moderate to severe anaphylaxis after re-administration of ICM is below 1% 
(53).
b) Practical Statement: The most important step in the evaluation of an IHR to ICM is a thorough 
history in order to establish the severity of the reaction. An isolated urticarial skin reaction 
represents a mild IHR, and anaphylactic shock is the most severe form. Allergy work-up for 
(presumably IgE-mediated) immediate-type, allergic ICM hypersensitivity includes SPT undiluted, 
IDT with a dilution of at least 1:10 (highest sensitivity), BAT (facultative), and DPT (if needed). 
Unfortunately, at present only a minority of patients with ICM-induced IHR undergo allergy testing 
and, therefore, in many patients ICM are re-administered without prior testing.
Moreover, in clinical practice the culprit ICM is often unknown, as documentation in radiology and 
cardiology departments is often restricted to the total volume of the injected ICM, whereas the 
exact name of the ICM is not always mentioned. Premedication with H1 antihistamines and 
corticosteroids may prevent recurrence in mild to moderate immediate reactions (5, 54). However, 
as premedication has not been shown beneficial in moderate/severe IHR and corticosteroids 
might induce substantial side effects, its use is becoming more and more controversial and 
applying an alternative skin test-negative ICM without premedication is a valid option and may 
perhaps become the standard in the future, after more experience is being generated (55)  
Recommendations (Fig 1)
- All patients with ICM-induced IHR should undergo allergy testing in order to diagnose or exclude 
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- If STs are negative there is no evidence for an ICM allergy, rather for a non-allergic ICM 
hypersensitivity, which is mostly mild to moderate in severity. The options are to give an 
alternative ICM with premedication or to perform a DPT to confirm tolerability. 
- As an approach for patients with a convincing history of ICM-induced IHR (no allergy testing 
yet), in which ICM-based radiological imaging is urgently needed, these steps can be followed: 
(i) If IHR is limited to the skin, i.e. urticaria with or without angioedema: ICM can be administered 
after pre-medication (strong/high). If the culprit ICM is known, an alternative ICM should be used.
(ii) Moderate to severe IHR (full-blown anaphylaxis): omit ICM and perform native computed 
tomography (CT)- or magnetic resonance (MR)-scan instead; if ICM is indispensable, administer 
the ICM after pre-medication and in anaesthesia stand-by (strong/low). If the culprit ICM is 
known, an alternative ICM should be used (strong/high).
6.- When is premedication recommended?
a) Background: Premedication with systemic corticosteroids and H1-antihistamines has been 
widely used to reduce the rate of IHR although its effectiveness has not been properly 
documented and there is no gold standard of premedication regimens. Moreover, premedication 
is not able to suppress all IHRs and some patients may develop breakthrough reactions. 
Usually, the premedication protocol consists in a combination of a multidose corticosteroid and an 
antihistamine (e.g. prednisone 13 h, 7 h and 1 h prior to ICM exposure with diphenhydramine 1 h 
prior to ICM exposure) (56-58). Lee et al. (54) reported the result of a study to evaluate the 
benefit of a severity-tailored prophylaxis in patients at risk of recurrent hypersensitivity reactions 
to ICM. Chlorpheniramine and methylprednisolone were recommended according to a severity 
index, and an alternative ICM based on a negative ST was used for patients with near-fatal 
anaphylactic shock or life-threatening reactions. In the group of patients with mild reactions, the 
prophylaxis with antihistamines plus corticosteroids did not produce significant beneficial 
outcomes compared with pretreatment with only antihistamines. However, in patients with severe 
reactions, the frequency of breakthrough reactions was reported to decrease when patients were 
premedicated with chlorpheniramine and corticosteroids two and 12 hours before. In general, 
using an alternative ICM protected for developing a reaction. They recommended that for patients 
with mild reactions, antihistamines can be a safe alternative option on re-exposure, and that the 
steroid dose should be stratified according to the severity of the previous reaction. However, the 
benefit of adding H2-antihistamines is not sufficiently demonstrated, and they are not routinely 
administered (59-61). Moreover, corticosteroid premedication has been discussed to be 
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The minimal interval for premedication administration is unknown. A 12-h or 13-h oral scheme of 
corticosteroids is usually recommended but an accelerated intravenous scheme is proposed 
when the multidose schedule is not feasible (54, 55). 
Premedication has not been considered sufficient and might not even be indicated in patients with 
a history of true IgE-mediated ICM anaphylaxis (55, 63, 64). Lee et al. observed 6/9 selected 
high-risk patients to be ST positive (54), and Marshall et al. observed 2/10 positive DPTs (60), 
indicating a subgroup of type I allergic patients. 
Currently, some American and European associations suggest changing ICM within the same 
class of low-osmolar ICM (58, 65). Several recent studies have demonstrated that changing ICM 
in mild reactions to low-osmolar ICM reduced the rate of breakthrough reactions (54, 66, 67).  
Some authors found that changing the ICM was more effective than premedication in prevention 
of recurrence reactions (66). Others found that the recurrence rate of mild IHR was 31.1% when 
patients were re-exposed to the same ICM without premedication (67). When the ICM was 
changed, the recurrence rate of IHR was 12% and with the addition of antihistamine 
premedication the rate was 7.6%. 
b) Practical Statements: Some American associations advise premedication for all patients with 
an “allergic-like” or unknown-type contrast reaction (57). However, European guidelines (65) 
recently removed the suggestion of invariably using premedication in patients at risk and 
emphasized the need to undergo an allergy evaluation to confirm or exclude an IgE-mediated 
drug allergy to ICM and to identify safe alternatives. They advised to change the ICM when it is 
known, since the use of an alternative ICM has proven more helpful in reducing the rate of 
recurrent IHR to ICM (54, 66). If the culprit ICM is unknown and there is an urgent need for ICM, 
premedication with H1 antihistamines and corticosteroids may prevent recurrence in mild to 
moderate immediate reactions (5, 56, 57).
In patients with a history of a prior severe reaction, re-administration of ICM is a relative 
contraindication, but if necessary and in the absence of alternatives, premedication should be 
considered, although evidence for efficacy is lacking in high-risk patients. In patients with a 
history of moderate-to-severe reaction, a higher dose of corticosteroids than usually used could 
be considered (54). 
Recommendation 
- Premedication is not a general recommended approach (high/strong). 
- In cases the culprit ICM is unknown and ICM administration is needed premedication could 
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NIHR to ICM range from unspecific and toxic symptoms (such as local pain or local wheal at the 
injection site, generalized pruritus, transient erythema, dizziness, nausea) to severe cutaneous 
adverse reactions. These latter reactions are mainly T-cell mediated, in skin biopsies a 
perivascular infiltrate of CD4+ and CD8+ T-cells has been uniformly demonstrated, and positive 
delayed STs are common. Recently, it has been demonstrated that DRESS syndrome due to ICM 
occurs with a very short delay, within the week following the ICM injection (68). Positive 
lymphocyte transformation tests (LTT) and ICM-specific T-cell clones have been demonstrated in 
some patients (69). The immunological reaction in patients with NIHR is directed against the 
structure of the ICM and not against the iodine ion in the vast majority of patients. NIHR to ICM 
are characterized by a T-cell mediated mechanism, appearing from hours to days after 
administration of the ICM. Delayed appearing non-allergic urticaria and/or angioedema occurring 
> 6 hours after ICM administration seem to be caused by a different, poorly understood 
mechanism.
Non-ionic dimeric ICM induce significantly more often cutaneous NIHRs than non-ionic 
monomeric ICM (70). In fact, more than 50% of MPE are induced by the non-ionic dimeric ICM 
iodixanol (71). 
1.- What are the indications for testing?
a) Background: As for IHR, NIHR to ICM may vary from uncomplicated MPE to complex 
hypersensitivity reactions such as DRESS or severe and life-threatening bullous drug reactions 
such as SJS/TEN. The most frequent clinical manifestation is mild to moderate MPE (3, 6, 9, 10, 
27, 69). A history of a previous ICM-induced adverse reaction is a predisposing factor for NIHR.  
b) Practical statement: Allergy testing is indicated in patients with clinical history indicative of 
MPE, FDE, SDRIFE, or AGEP. In severe bullous skin reactions and in DRESS, ST is 
recommended, whereas DPT is generally contraindicated, although even in these cases 
exceptions are possible depending on the risk of a renewed severe reaction and urgent need. 
Although the mechanisms underlying delayed-appearing urticaria and angioedema are not well 
understood, they should be studied. 
Recommendations
- To identify patients with T cell-mediated reactions to ICM and to provide guidance on tolerability 
of alternatives, all patients with a suspicion of ICM-induced exanthema should be tested 
(strong/moderate).  
- Delayed-appearing urticaria and angioedema are usually ST-negative (weak /low).
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a) Background: An immunological, T-cell mediated mechanism has been demonstrated for the 
various clinical manifestations of NIHR by delayed reading IDT and patch test (PT), immune-
histological findings, and specific proliferation of T-cells in vitro (5, 72-74). STs can be helpful to 
identify the responsible ICM and to find alternative ICM (3, 5, 6, 20, 21, 27, 29, 37, 46, 69, 72, 75, 
76). In a European multicentre study, 98 patients with NIHR to ICM were investigated by SPT, 
IDT, and PT using the suspected culprit and a variety of other ICM of all four chemical subgroups 
(6). STs with delayed reading were positive in 38/98 patients (38%, 95% CI 28-47%), with 32% 
being positive in the IDT with late reading, 28% in the PT, and only 3% in the SPT with delayed 
reading, some patients tested positive in only one test. A meta-analysis on STs in hypersensitivity 
reactions to ICM found the overall positive rate for STs in NIHR to be 26% (95% CI, 15-41%), for 
SPT 7% (95% CI, 1-30%), for IDT 22% (95% CI, 13-34%), and for PT 16% (95% CI, 9-26%), and 
an added value if IDT and PT were combined and the suspected culprit was included (29). No 
false-positive STs were found in six European studies on NIHRs. If four or more ICM were tested, 
ST-negative ICM were detectable in 90% of cases (95% CI 77-96%) (29). IDT performed 
between 1 and 6 months after the resolution of the hypersensitivity reactions showed higher 
positive rates (48%) than if later performed (23%, p=0.02) (6). IDTs are generally carried out at 
1:10 dilutions for IHR and NIHR, but up to 70% of IDT reacted to the undiluted ICM with good 
safety without generating false positive IDT and it may be used if the immediate reading of the 
1:10 dilution is negative (69). For SCARs however, where very little information on ST is 
available, it is not advisable to proceed directly to undiluted ICM in IDT, and a safe stepwise 
approach starting with PT, followed by IDT 1:10, and finally IDT 1:1 in which for each step 
delayed reading is performed prior to proceeding to the next step, should be considered.
Regarding the NPV of STs, whereas two older smaller studies had reported a lower NPV (69, 72), 
, a meta-analysis and larger studies performed afterwards highlighted the usefulness of STs for 
identifying safe alternatives (21, 29, 77), and a NPV of 86.1% (IC95% : 72.1-94.7%) has been 
calculated in the largest study (21). Milder flare-up reactions upon IDT in NIHR seem to be rare, 
but possible (72). 
b) Practical Statement: For IDT, 1:10 dilutions of the standard ICM solution are non-irritative (6). 
However, the sensitivity of IDT with delayed reading in NIHR seems to be higher if undiluted ICM 
concentrations are used (69). In that case, the frequent difficulty to interpret immediate reaction 
needs to be ignored as it does not represent a sign of an immediate IgE-mediated allergy. IDT 
with undiluted ICM may induce irritative large uncoloured wheals after 20 minutes without 
surrounding erythema, possibly due to the osmolarity of the products, which may be difficult to 
distinguish from a positive IDT (large wheal with a surrounding erythema). IDTs should ideally 
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tested undiluted. PTs should have two readings:  at the moment of removal (after 48 hours), and 
a delayed reading 72-120 hours later (6). Due to the possibility of later appearance of skin 
reactions, patients should be instructed to report any skin reaction at the test site.
Some patients with FDE or SDRIFE might exhibit negative STs, if tested only on the upper arms 
or upper back. In FDE testing should be done at the previous involved area by in situ PT (78). A 
potential explanation could be the presence of drug specific resident memory T-cells at the site of 
the clinical reaction, which seem to be more reactive upon local challenge (skin testing) than 
central memory T-cells (79).
Allergological work-up should be ideally performed within 6 months after the clinical reaction 
since sensitivity of the tests is reduced thereafter (69).
Recommendations
- When to test: ideally within the first 6 months after the clinical reaction and more than 6 months 
in case of DRESS (weak /low).
- What to test: ideally the suspected culprit and several commonly used alternatives due to the 
extended cross-reactivity in NIHR (strong/moderate). In DRESS and FDE, patch tests can be 
useful and SPT and IDT should not be used (weak /low).
- How to test: IDT with 1:10 dilution of the standard concentration of ICM or undiluted on the 
upper arm or upper back with delayed reading after 48 and 72 hours (weak /low). PT on the 
upper back with undiluted standard solution of ICM with reading at 48 hours and a delayed 
reading (72-120 hours) (strong /low). Patients should be instructed to return for additional 
readings in case of any later appearing skin reaction at the test site (weak/low). Using both tests 
may enhance sensitivity (weak /low). If all tests are negative: Consider IDT and/or PT with 
undiluted ICM in local testing, especially in FDE (weak /low). 
3.- What is the value of the Lymphocyte Transformation Test?
a) Background: LTT measures the proliferation of T-cells after stimulation with a drug in vitro. It 
aims to detect circulating drug-specific memory T-cells, which proliferate upon drug (= antigen) 
stimulation. In most cases, proliferation is measured as 3H-thymidine uptake as counts per 
minutes (cpm). Generally, results are given as stimulation index in relation to unstimulated cells. 
The sensitivity and specificity of the LTT must be newly defined for each antigen. It has been 
used to demonstrate specific recognition of ICM by T lymphocytes in patients with NIHR (73, 74).
LTT results in NIHR to ICM are heterogeneous and the sensitivity ranges from 13 to 75%, 
variability probably related to the number of patients studied, their clinical characteristics, the 
diagnostic approach used, and the expertise of the diagnostic laboratory (80). LTT can only be 
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NIHR (5). b) Practical Statement: LTT is not recommended at the acute stage, but rather after 4–
8 weeks after remission (81) and within 2–3 years after the reaction (82). Corticosteroids in doses 
higher than 0.2 mg/kg body weight prednisone equivalent and other immunosuppressive or 
immunomodulatory agents may interfere with the test. A NPV for LTT in NIHR to ICM is not 
available. As radioactive materials have been banned in many laboratories the use of "modified 
non-radio-active LTT" will be a better choice.
Recommendations
- The LTT can be done as an additional diagnostic tool in selected cases with contraindications 
for STs (weak /low).
- It should only be performed by experienced physicians (weak /low).
4.- Is there a role for DPT? 
a) Background: DPT with ICM can be necessary to rule out the diagnosis and to identify 
alternative ICM that can be used in subsequent radiological examinations, if hypersensitivity to 
ICM is confirmed (5, 26, 46, 69, 72, 83). The ICM chosen for DPT will depend on ST results  and 
reaction severity. The polyvalent reactivity seems higher in NIHR than in IHR (6, 13, 21, 37, 69, 
74, 80). The most frequently association has been found between iodixanol and iohexol (6, 37, 
69), and between ioversol and iomeprol (21).
b) Practical Statement: DPT with the culprit ICM may rule out the diagnosis of NIHR in patients 
with non-severe reactions, and with an alternative in patients with confirmed NIHR or with severe 
reactions (3). It has been reported that DPT identified NIHR to ICM in up to 41.7%-56.4% of 
negative ST patients (69, 72). It has been reported that iobitridol shows low cross-reactivity in 
patients with NIHR to other ICM (76). 
Several modalities of DPT with ICM have been reported with no consensus regarding the total 
dose or intervals of DPT, e.g.: (i) increasing doses at 1-h intervals in two runs separate by 1 week 
(5-10-15 mL on the first day and 20-30-50 mL (cumulative dose: 100 cc) on the second day) (10); 
(ii) 5-20 mL of iobitridol at 1-hour interval and two 50 mL doses at 1-hour interval (cumulative 
dose: 100 mL) the following week (76); (iii) 1/100 of the dose required for radiological examination 
and 1–24 h later 1/10 of the dose required (37, 72); (iv) 0.05-0.5-1-5-7.5-10-25 mL at 30-min 
interval (13, 51). In patients with NIHR, premedication is not effective (84, 85).  
Recommendations
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- The ICM chosen for DPT may be the culprit in patients with non-severe reactions and negative 
ST, and a ST-negative alternative in patients with confirmed NIHR or with severe reactions 
(weak/low).
- Renal function need to be carefully monitored (strong/high).
- Available protocols should be standardized (strong/high).
5. How should a patient be evaluated
a) Background: MPE developing several (mostly 6-12) hours after administration seems to 
account for the great majority of NIHR (6, 69, 86). An exanthematous skin eruption is classified as 
uncomplicated MPE if signs of a systemic reaction such as fever, hepatitis or nephritis are 
virtually absent. In addition, single cases of FDE, flexural exanthema, AGEP and even life-
threatening DRESS, SJS and TEN have been described as ICM-induced NIHR (3, 7, 80).
b) Practical statement: In ICM-related MPE, allergy testing is mandatory to reliably confirm or 
exclude ICM as cause of the skin rash. It should be borne in mind that only few patients with MPE 
show a positive test result. Otherwise, many patients may be unjustified labelled as ICM allergic. 
In non-severe MPE, the moderate sensitivity and high specificity of STs (performed within 6 
months after the clinical reaction) for diagnosis of allergic NIHR in combination with a limited risk 
(reoccurrence of a MPE) implies that diagnostic DPT is often not necessary. In patients sensitized 
to several ICM, DPT may be advisable to prove that a certain ST-negative ICM is definitely 
tolerated (69).
Recommendations (Fig. 2)
- The first and most important step in the evaluation of patients with suspected ICM-induced 
NIHR is a thorough history (high/strong). 
- An uncomplicated MPE should be clearly separated from other clinical reaction patterns 
(high/strong).
- If there are hints in history or medical documents suggesting a morphologically unusual skin 
eruption, a systemic reaction including hepatitis or nephritis, or a bullous skin reaction with 
mucosal involvement, diagnostic testing (ST and DPT) must be based on individual risk-benefit 
considerations or is even contraindicated (high/strong).
- The evaluation of patients with ICM-associated MPE should include IDT and PT ensuring that 
patients with allergic ICM hypersensitivity are not missed (low/strong). Moreover, skin testing may 
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- If clinical history, information from treating physicians, caregivers or medical records 
unambiguously indicate an uncomplicated MPE and there is an urgent diagnostic need, ICM may 
be administered based on individual risk-benefit considerations (low/weak).
6.- When is premedication recommended?
a) Background: No studies have systematically evaluated the use of premedication for prevention 
or recurrences of NIHR. Although it has been indicated that corticosteroids premedication in 
patients with previous NIHR to ICM may be useful (57), repeated reactions, including a case of 
TEN, have been described (3, 84, 86, 87).
b) Practical statements: There is no evidence for a premedication in patients with NIHR and this 
can be especially harmful in patients with a history of a severe NIHR (e.g. TEN, DRESS). 
Recommendation 
- There is no evidence to prove the efficacy of premedication in patients with NIHR to ICM 
(high/strong).
OPEN QUESTIONS FOR IMMEDIATE AND NON-IMMEDIATE REACTIONS
1.- Is there any cross-reactivity among ICM? 
Currently, it is not clear whether ‘cross-reactivity’ does exist or not and further studies are 
needed. In clinical studies, multiple reactions are regularly observed, in 67% of the 97 patients 
having at least one positive ST with ICM, STs and re-administration of other ICM may induce 
reaction (37). In studies with smaller populations, it varies a lot: from 20% (n= 15) (88), 26% (n= 
15) (72), 27% (n= 22) (69), 43% (n= 80) (21) to 75% (n= 36) (6).  Cross-reactivity is neither 
related to iodine, nor to excipients contained in ICM, nor to their ionicity. In NIHR, cross reactions 
could be related to the presence of the carbamoyl side chain in some ICM. Hasdenteufel et al. 
(75) reported that only 2 of 22 patients sensitized to iodixanol also reacted to iobitridol. In NIHR 
Gracia-Bara et al. (89) also observed a very few numbers of reactions between iobitridol and 
other ICM. Preferential multiple reactions are summarized in Table 2.
Recommendation: 
- Further studies are needed to understand better multiple reactions against ICM (strong 
/moderate). 
2.- What else in the management? 
Radiologists should be prepared to recognize and treat the various types of adverse reactions to 
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period, adrenaline was only used in 9 out of 457000 cases, being laryngeal oedema the most 
frequent symptom (N=6) (90). Only 41% of radiologists gave the correct treatment of adrenaline 
to an IHR (91). Similar studies indicated lacking radiology resident preparedness for paediatric 
life-threatening events (92). Thus, radiologists’ use of adrenaline should be improved by training. 
Computerized guidelines for the detection and management of patients with ICM hypersensitivity 
reactions have proven to be effective not only in gaining epidemiological data, but also in 
standardizing the management and reducing adverse events in patients with previous ICM 
hypersensitivity reactions (93, 94).
There has been a concern that IHR to ICM might be more common in systemic mastocytosis 
(SM), as patients with SM frequently develop anaphylaxis to several triggers (95, 96). However, 
there is no evidence that there is a greater risk of IHR to ICMs in patients with SM compared with 
the general population. Only few individual cases with IHR to ICMs have also been described in 
patients with SM and SM has not ever been reported as an underlying disease in patients with 
fatal RCM-induced anaphylaxis (97). Nevertheless, in all patients with previous anaphylaxis to 
ICM, baseline serum tryptase should be determined to screen for mastocytosis. Additionally, 
patients with SM should also undergo allergy testing to ICMs. Before administering ICMs to adults 
with mastocytosis, emergency preparedness is necessary and resuscitation facilities should be 
nearby.
Recommendations 
- Radiologists should improve emergency awareness and training on emergency treatment of 
ICM IHR (high/strong). 
- In all patients with previous anaphylaxis to ICM, baseline serum tryptase should be determined 
to screen for mastocytosis (low/weak). 
- Emergency preparedness is needed before administering ICMs to adults with mastocytosis, and 
resuscitation facilities should be nearby (low/weak).
CONCLUSIONS
Hypersensitivity reactions to ICM are still a challenge. It is pivotal to have a good clinical history, 
but also to evaluate the medical record for discordances, uneventful re-expositions that might 
help the choice for a safe ICM. STs are recommended to identify patients with IgE- or T cell-
mediated reactions to ICM and to provide guidance on tolerability of alternatives. BAT can be an 
additional tool for diagnosing patients with IHR with severe reactions or those with high risk. LTT 
for NIHR may be an alternative when STs cannot be performed. DPT is the gold-standard but the 
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should be done only in well-equipped centres and by trained personnel. There is no evidence of 
the efficacy of premedication in patients with severe IHR, IgE-mediated reactions, and NIHR to 
ICM. Further studies are needed to better understand multiple reactions against ICM. Allergist 
should convince patients and physicians of the usefulness of critically evaluating the ICM allergy 
label(s) early-on.
Table 1. Management of patients with previous hypersensitivity reaction to ICM
Management Advantages Disadvantages Comment Ref
Avoidance Safety Diagnosis not achieved To be considered in 
patients in which other 
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Table 2. Data on reported cross-reactivity of ICM in NIHR (adapted from (37)).
Group A Reported cross reactivities between molecules  
and references
Without carbamoyl chain: 
Ioxithalamate (IM)
With carbamoyl chain: 
Iodixanol (NID) HF of CR with iohexol (iodixanol is the dimer of 
iohexol) (6, 37, 69, 72) 
HF of CR with iomeprol and ioversol (6)
Iohexol (NIM) HF of CR with iodixanol (iodixanol is the dimer of 
iohexol) (6, 39, 68, 72)
HF of CR with iomeprol and ioversol (6)
Ioversol (NIM) HF of CR with iodixanol, iohexol and iomeprol (6)
LF of CR with iopamidol (88)
Iomeprol (NIM) HF of CR with iodixanol, iohexol and ioversol (6)
HF of CR with Iopromide (19)
Iopamidol (NIM) LF of CR with ioversol (88)
Iopromide (NIM) Less investigated, HF of CR with Iomeprol (21)
Group B
   Iobitridol (NIM)
   Ioxaglate (ID)
Group C
Amidotrizoate (IM)
IM: ionic tri-iodized monomer, NIM: non-ionic tri-iodized monomer, ID: ionic hexa-iodized dimer, NID: non-
ionic hexa-iodized dimer, HF: high frequency, CR: cross reactivity, LF: Low frequency.
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